Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Operating Expenses (2018 - 2025)

X4 Pharmaceuticals' Operating Expenses history spans 8 years, with the latest figure at $157.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 85.54% year-over-year to $157.8 million; the TTM value through Dec 2025 reached $116.2 million, down 39.25%, while the annual FY2025 figure was $116.2 million, 198.37% up from the prior year.
  • Operating Expenses reached $157.8 million in Q4 2025 per XFOR's latest filing, up from -$11.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $157.8 million in Q4 2025 to a low of -$19.7 million in Q1 2025.
  • Average Operating Expenses over 5 years is $29.4 million, with a median of $25.4 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: skyrocketed 237.43% in 2024, then crashed 152.93% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $29.1 million in 2021, then fell by 11.97% to $25.6 million in 2022, then fell by 1.48% to $25.2 million in 2023, then surged by 237.43% to $85.0 million in 2024, then skyrocketed by 85.54% to $157.8 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Operating Expenses are $157.8 million (Q4 2025), -$11.9 million (Q3 2025), and -$9.9 million (Q2 2025).